Figure 2. The influence of Sutent monotherapy on the CD11b+ populations in tumors and peripheral blood. (A) The gating scheme showed that tumor-associated CD11b+ myeloid cells could be classified into three subpopulations including CD11b+Ly6G+Ly6C+ PMN-MDSCs (symbol a), CD11b+Ly6G–Ly6C+ M-MDSCs/TAMs (symbol b) and CD11b+Ly6G–Ly6C– TAMs (symbol c). These subpopulations were further examined by macrophage markers, such as CD68 and CD206 (mannose receptor, also known as pro-tumoral M2 marker). (B) The t-distributed stochastic neighbor embedding (tSNE) illustration showed the heterogeneity of total CD11b+ myeloid cells in VE7D tumors. (C) The gating scheme revealed that the circulating CD11b+ myeloid cells in peripheral blood could be briefly classified into three subpopulations, such as CD11b+Ly6G+Ly6C+ PMN-MDSCs (symbol d), CD11b+Ly6G–Ly6Chi M-MDSCs (symbol e) and CD11b+Ly6G–Ly6C– monocytes (symbol f). The percentages of (D) total CD11b+ cells, (E) CD11b+Ly6G–Ly6C– TAMs, (F) CD11b+Ly6G+Ly6C+ PMN-MDSCs and (G) CD11b+Ly6G–Ly6C+ TAMs/M-MDSC in tumors were quantified by flow cytometry (N=5 in each group). The populations of (H) total CD11b+ cells, (I) CD11b+Ly6G–Ly6C– resident monocyte, (J) CD11b+Ly6G+Ly6C+ PMN-MDSCs and (K) CD11b+Ly6G–Ly6C+ M-MDSCs, in blood samples were determined (N≥4 in each group).